Mylan Receives FDA Approval for Levothyroxine Sodium TabletsPITTSBURGH, June 24 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Levothyroxine Sodium Tablets in 0.025 mg, 0.050 mg, 0.075 mg, 0.088 mg, 0.1 mg, 0.112 mg, 0.125 mg, 0.15 mg, 0.175 mg, 0.2 mg and 0.3 mg strengths.

Levothyroxine Sodium Tablets are the generic version of Abbott Laboratories' Synthroid^® Tablets.

"We are very pleased with this product approval," stated Robert J. Coury, Mylan's Vice Chairman and CEO. "This approval represents a very important addition to our product portfolio and finally brings closure to some of the tactics used by others to delay legitimate generic approvals."

The product will be shipped immediately.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.

This press release includes statements that constitute "forward-looking statements," including with regard to the immediate shipment of Levothyroxine Sodium Tablets and the significance of the approval to the Company's product portfolio. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the possible negative effects of any interruption of manufacture of the product at the Company's facility; uncertainties regarding market acceptance and demand for the product; dependence on third-party suppliers and distributors for raw materials; the potential costs and product introduction delays that may result from use of legal, regulatory and legislative strategies by the Company's competitors; and the other risks detailed in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

For more information about Mylan, visit www.mylan.com.

SOURCE Mylan Laboratories Inc.
06/24/2004
CONTACT:
Heather Bresch, Media, or Kris King, Investor
both of Mylan Laboratories
+1-724-514-1800
Web site: http://www.mylan.com